Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
Running, not enrolling · Phase 2
Conditions studied: Multiple Myeloma
In brief
This phase 2 trial will test whether the combination of DaraRd (daratumumab + lenalidomide + dexamethasone) as induction therapy, followed by DRVd (daratumumab + lenalidomide + bortezomib + dexamethasone) consolidation therapy, if needed, will result in more patients achieving minimal residual disease (MRD)-negative status, relative to the standard of care. Consolidation therapy will be administered only to those patients with MRD-positive status after induction therapy. This is a study based on adaptive design for decision making of treatment options. Duration of therapy (daratumumab cycles) will depend on individual approach, response, evidence of disease progression and tolerance.
Key facts
- Study ID
- NCT04140162
- Run by
- University of Michigan Rogel Cancer Center
- People needed
- 57
- Starts
- 2020-10-05
- Expected to finish
- 2026-09-02
- Last updated by the study team
- 2026-07-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan, United States
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
- University of Rochester — Rochester, New York, United States
- University of Texas Southwestern -- Simmons Comprehensive Cancer Center — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.